Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Metastatic Thyroid Carcinoma
NCT00095693Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in thyroid cancer, sponsored by National Cancer Institute. Started Oct 2004; status: terminated.
02
Drugs
sorafenib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00095693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095693.